Eyal Meiri, MD

Description

Dr. Eyal Meiri earned his medical degree from University of Toronto and completed his residency at Sinai Hospital of Detroit. He is fellowship-trained in oncology and hematology and is board certified in Internal Medicine and Medical Oncology. Prior to joining Piedmont, he was the Chief of Medical Oncology at Cancer Treatment Centers of America. Dr. Meiri has been practicing medicine for over 33 years and specializes in GI Cancers and Neuroendocrine Tumors. In his spare time, Dr. Meiri enjoys spending time reading, listening to audio books and podcasts, traveling, the Toronto Maple Leafs, and live concerts. Dr. Meiri is accepting new patients and welcomes most major insurance plans.

Keywords cervical and endometrial cancers, cervical cancer, autoimmune cytopenia, xanthogranuloma, vulvar cancer chemotherapy, vocal cord cancer, vaginal cancer chemotherapy, uterine cancer chemotherapy, transurethral resection of bladder, tracheal cancer chemotherapy, tongue cancer chemotherapy, throat cancer chemotherapy, teratogen exposure, systemic therapy, stomach cancer chemotherapy, squamous cell carcinoma of penis, squamous cell carcinoma of bladder, squamous cell carcinoma, spleen cancer chemotherapy, spine mets, solid tumors, small intestine cancer chemotherapy, small cell lung cancer chemotherapy, skin cancer on penis, skin cancer of the face, skin cancer, sinus cancer, rib cancer, renal sarcoma, renal pelvis carcinoma, renal cell carcinoma immunotherapy, relapsed non hodgkin lymphoma, post radiation pain, pleural cancer chemotherapy, personalized cancer therapy, penile cancer chemotherapy, paraneoplastic cerebellar degeneration (pcd), pancreatic cancer chemotherapy, palate cancer, ovarian cancer chemotherapy, orbit cancer, onco nephrology, octreotide treatment, non-muscle invasive bladder cancer, nasopharyngeal cancer chemotherapy, muscle invasive bladder cancer, multi-cancer early detection blood test, mouth cancer chemotherapy, melanoma surgery, mediastinal lymphadenopathy, malignant spindle cell neoplasm, malignant lung tumors, malignant granular cell tumor, lung cancer, liver cancer chemotherapy, liquid biopsy testing, laryngeal cancer chemotherapy, large cell neuroendocrine tumors, large cell cancer of the lung, lacrimal gland cancer, kidney cancer, intravesical chemotherapy, immunoassay for tumor antigen ca 15-3 and ca 27-29, immunoassay for tumor antigen ca 125, hypopharyngeal cancer chemotherapy, human t-cell lymphotropic virus type 2, human t-cell lymphotropic virus type 1, histiocytoma, hereditary papillary renal cell cancer, hereditary kidney cancer, hepatic artery infusion pump placement, head and neck cancer chemotherapy, glottic cancer, gleason score, germinoma, gastrointestinal (gi) cancer, gallbladder cancer chemotherapy, gallbladder cancer, familial renal cell carcinoma, face cancer, eyelid cancer chemotherapy, eyelid cancer, eye cancer chemotherapy, eye cancer, esophageal cancer chemotherapy, esophageal cancer, endometrial cancer chemotherapy, electrolyte abnormalities in cancer patients, egfr translocation, egfr mutation, diaphragm cancer, colorectal cancer chemotherapy, colon cancer chemotherapy, cervical cancer chemotherapy, cancer risk, cancer of the muscles, cancer of the joints, breast cancer chemotherapy, biliary tract cancer chemotherapy, appendiceal cancer chemotherapy.